Compare · DRNA vs GWPH
DRNA vs GWPH
Side-by-side comparison of Dicerna Pharmaceuticals, Inc. (DRNA) and GW Pharmaceuticals Plc (GWPH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DRNA and GWPH operate in Major Pharmaceuticals (Health Care), so they compete in similar markets.
- DRNA carries a market cap of $2.96B.
- DRNA has more recent analyst coverage (14 ratings vs 0 for GWPH).
- Company
- Dicerna Pharmaceuticals, Inc.
- GW Pharmaceuticals Plc
- Price
- $38.23+0.61%
- $219.01-0.21%
- Market cap
- $2.96B
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Major Pharmaceuticals
- Major Pharmaceuticals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2014
- 2013
- News (4w)
- 0
- 0
- Recent ratings
- 14
- 0
Dicerna Pharmaceuticals, Inc.
Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercializing of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare, cardiometabolic, viral, and chronic liver diseases; complement-mediated diseases; and neurodegenerative diseases and pain. Its principal development programs include nedosiran for the treatment of primary hyperoxaluria; RG6346 for the treatment of chronic hepatitis B virus infection; belcesiran for the treatment of deficiency-associated liver disease; and DCR-AUD for the treatment of alcohol use disorder. Dicerna Pharmaceuticals, Inc. has strategic collaborations with Novo Nordisk A/S, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
Latest DRNA
- Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer
- SEC Form 15-12B filed by Dicerna Pharmaceuticals, Inc.
- SEC Form EFFECT filed by Dicerna Pharmaceuticals, Inc.
- SEC Form EFFECT filed by Dicerna Pharmaceuticals, Inc.
- SEC Form EFFECT filed by Dicerna Pharmaceuticals, Inc.
- SEC Form EFFECT filed by Dicerna Pharmaceuticals, Inc.
- SEC Form 4: Koppel Adam closing all direct ownership in the company
- SEC Form 4: Zeng Ling closing all direct ownership in the company
- SEC Form 4: Weissman James B closing all direct ownership in the company
- SEC Form 4: Smith Cynthia closing all direct ownership in the company
Latest GWPH
- IDEAYA Biosciences Appoints Douglas B. Snyder as Senior Vice President, General Counsel
- Jazz Pharmaceuticals Files Patent Infringement Against Generic Drugmakers In New Jersey's District Court
- Study Suggests Whole-Plant Medicinal Cannabis Could Be More Effective Than CBD In Epilepsy Treatment
- SEC Form 15-12B filed by GW Pharmaceuticals Plc
- SEC Form 4: Tovey Christopher J. returned 2,496 units of Ordinary Shares to the company, decreasing direct ownership by 100% to 0 units
- SEC Form 4: Cline Darren S returned 5,556 units of Ordinary Shares to the company, decreasing direct ownership by 100% to 0 units
- SEC Form 4 filed by GRYSKA DAVID W
- SEC Form 4: Giacobello Scott M. returned 165,108 units of Ordinary Shares to the company, decreasing direct ownership by 100% to 0 units
- SEC Form 4: Secor Alicia returned 10,584 units of Ordinary Shares to the company, decreasing direct ownership by 100% to 0 units
- SEC Form 4: Knappertz Volker returned 92,412 units of Ordinary Shares to the company, decreasing direct ownership by 100% to 0 units